arsenic trioxide oral (QTX-2101) / Quetzal Therapeutics - LARVOL DELTA

Quetzal Therapeutics…announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to QTX-2101, the company’s investigational oral arsenic trioxide capsule, for the treatment of patients with acute promyelocytic leukemia (APL). (GlobeNewswire) - "QTX-2101 is currently being evaluated in a global, multicenter, randomized, controlled Phase III clinical trial comparing the investigational oral capsule to standard-of-care therapy in patients with newly diagnosed APL."

Fast track • Acute Promyelocytic Leukemia

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL) (GlobeNewswire) - "This global, multicenter, randomized, controlled study will compare QTX-2101 to standard-of-care therapy in patients with newly diagnosed APL."

New P3 trial • Acute Promyelocytic Leukemia